世界のスミス・マゲニス症候群治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Smith-Magenis Syndrome Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A11906
• 出版社/出版日：GlobalInfoResearch / 2021年7月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、108ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料では、スミス・マゲニス症候群治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。スミス・マゲニス症候群治療の種類別市場規模（薬品、手術、その他）、用途別市場規模（病院、専門クリニック、在宅ケア、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・スミス・マゲニス症候群治療の市場概要
・企業情報（企業概要、製品概要、販売量、価格、売上）：Rhythm Pharmaceuticals、Vanda Pharmaceuticals、Neurim Pharmaceuticals、Novartis、Takeda Pharmaceutical、Sanofi、Johnson & Johnson、Eisai、Teva Pharmaceutical Industries、Boehringer Ingelheim International、ALLERGAN、Roche Holding、Purdue Pharma、PhotoPharmics
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年：薬品、手術、その他
・用途別分析2016年-2026年：病院、専門クリニック、在宅ケア、その他
・スミス・マゲニス症候群治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ
・スミス・マゲニス症候群治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア
・スミス・マゲニス症候群治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア
・スミス・マゲニス症候群治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン
・スミス・マゲニス症候群治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Smith-Magenis Syndrome Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Smith-Magenis Syndrome Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Smith-Magenis Syndrome Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Smith-Magenis Syndrome Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Medicine
Surgery
Other

Market segment by Application, can be divided into
Hospital
Specialty Clinic
Homecare
Other

Market segment by players, this report covers
Rhythm Pharmaceuticals
Vanda Pharmaceuticals
Neurim Pharmaceuticals
Novartis
Takeda Pharmaceutical
Sanofi
Johnson & Johnson
Eisai
Teva Pharmaceutical Industries
Boehringer Ingelheim International
ALLERGAN
Roche Holding
Purdue Pharma
PhotoPharmics

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

1 Market Overview
1.1 Product Overview and Scope of Smith-Magenis Syndrome Treatment
1.2 Classification of Smith-Magenis Syndrome Treatment by Type
1.2.1 Overview: Global Smith-Magenis Syndrome Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Smith-Magenis Syndrome Treatment Revenue Market Share by Type in 2020
1.2.3 Medicine
1.2.4 Surgery
1.2.5 Other
1.3 Global Smith-Magenis Syndrome Treatment Market by Application
1.3.1 Overview: Global Smith-Magenis Syndrome Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Homecare
1.3.5 Other
1.4 Global Smith-Magenis Syndrome Treatment Market Size & Forecast
1.5 Global Smith-Magenis Syndrome Treatment Market Size and Forecast by Region
1.5.1 Global Smith-Magenis Syndrome Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Smith-Magenis Syndrome Treatment Market Size by Region, (2016-2021)
1.5.3 North America Smith-Magenis Syndrome Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Smith-Magenis Syndrome Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Smith-Magenis Syndrome Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Smith-Magenis Syndrome Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Smith-Magenis Syndrome Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Smith-Magenis Syndrome Treatment Market Drivers
1.6.2 Smith-Magenis Syndrome Treatment Market Restraints
1.6.3 Smith-Magenis Syndrome Treatment Trends Analysis
2 Company Profiles
2.1 Rhythm Pharmaceuticals
2.1.1 Rhythm Pharmaceuticals Details
2.1.2 Rhythm Pharmaceuticals Major Business
2.1.3 Rhythm Pharmaceuticals Smith-Magenis Syndrome Treatment Product and Solutions
2.1.4 Rhythm Pharmaceuticals Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Rhythm Pharmaceuticals Recent Developments and Future Plans
2.2 Vanda Pharmaceuticals
2.2.1 Vanda Pharmaceuticals Details
2.2.2 Vanda Pharmaceuticals Major Business
2.2.3 Vanda Pharmaceuticals Smith-Magenis Syndrome Treatment Product and Solutions
2.2.4 Vanda Pharmaceuticals Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Vanda Pharmaceuticals Recent Developments and Future Plans
2.3 Neurim Pharmaceuticals
2.3.1 Neurim Pharmaceuticals Details
2.3.2 Neurim Pharmaceuticals Major Business
2.3.3 Neurim Pharmaceuticals Smith-Magenis Syndrome Treatment Product and Solutions
2.3.4 Neurim Pharmaceuticals Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Neurim Pharmaceuticals Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Smith-Magenis Syndrome Treatment Product and Solutions
2.4.4 Novartis Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis Recent Developments and Future Plans
2.5 Takeda Pharmaceutical
2.5.1 Takeda Pharmaceutical Details
2.5.2 Takeda Pharmaceutical Major Business
2.5.3 Takeda Pharmaceutical Smith-Magenis Syndrome Treatment Product and Solutions
2.5.4 Takeda Pharmaceutical Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Takeda Pharmaceutical Recent Developments and Future Plans
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Smith-Magenis Syndrome Treatment Product and Solutions
2.6.4 Sanofi Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Sanofi Recent Developments and Future Plans
2.7 Johnson & Johnson
2.7.1 Johnson & Johnson Details
2.7.2 Johnson & Johnson Major Business
2.7.3 Johnson & Johnson Smith-Magenis Syndrome Treatment Product and Solutions
2.7.4 Johnson & Johnson Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Johnson & Johnson Recent Developments and Future Plans
2.8 Eisai
2.8.1 Eisai Details
2.8.2 Eisai Major Business
2.8.3 Eisai Smith-Magenis Syndrome Treatment Product and Solutions
2.8.4 Eisai Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Eisai Recent Developments and Future Plans
2.9 Teva Pharmaceutical Industries
2.9.1 Teva Pharmaceutical Industries Details
2.9.2 Teva Pharmaceutical Industries Major Business
2.9.3 Teva Pharmaceutical Industries Smith-Magenis Syndrome Treatment Product and Solutions
2.9.4 Teva Pharmaceutical Industries Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.10 Boehringer Ingelheim International
2.10.1 Boehringer Ingelheim International Details
2.10.2 Boehringer Ingelheim International Major Business
2.10.3 Boehringer Ingelheim International Smith-Magenis Syndrome Treatment Product and Solutions
2.10.4 Boehringer Ingelheim International Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Boehringer Ingelheim International Recent Developments and Future Plans
2.11 ALLERGAN
2.11.1 ALLERGAN Details
2.11.2 ALLERGAN Major Business
2.11.3 ALLERGAN Smith-Magenis Syndrome Treatment Product and Solutions
2.11.4 ALLERGAN Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 ALLERGAN Recent Developments and Future Plans
2.12 Roche Holding
2.12.1 Roche Holding Details
2.12.2 Roche Holding Major Business
2.12.3 Roche Holding Smith-Magenis Syndrome Treatment Product and Solutions
2.12.4 Roche Holding Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Roche Holding Recent Developments and Future Plans
2.13 Purdue Pharma
2.13.1 Purdue Pharma Details
2.13.2 Purdue Pharma Major Business
2.13.3 Purdue Pharma Smith-Magenis Syndrome Treatment Product and Solutions
2.13.4 Purdue Pharma Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Purdue Pharma Recent Developments and Future Plans
2.14 PhotoPharmics
2.14.1 PhotoPharmics Details
2.14.2 PhotoPharmics Major Business
2.14.3 PhotoPharmics Smith-Magenis Syndrome Treatment Product and Solutions
2.14.4 PhotoPharmics Smith-Magenis Syndrome Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 PhotoPharmics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Smith-Magenis Syndrome Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Smith-Magenis Syndrome Treatment Players Market Share
3.2.2 Top 10 Smith-Magenis Syndrome Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Smith-Magenis Syndrome Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Smith-Magenis Syndrome Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Smith-Magenis Syndrome Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Smith-Magenis Syndrome Treatment Revenue Market Share by Application (2016-2021)
5.2 Smith-Magenis Syndrome Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Smith-Magenis Syndrome Treatment Revenue by Type (2016-2026)
6.2 North America Smith-Magenis Syndrome Treatment Revenue by Application (2016-2026)
6.3 North America Smith-Magenis Syndrome Treatment Market Size by Country
6.3.1 North America Smith-Magenis Syndrome Treatment Revenue by Country (2016-2026)
6.3.2 United States Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Smith-Magenis Syndrome Treatment Revenue by Type (2016-2026)
7.2 Europe Smith-Magenis Syndrome Treatment Revenue by Application (2016-2026)
7.3 Europe Smith-Magenis Syndrome Treatment Market Size by Country
7.3.1 Europe Smith-Magenis Syndrome Treatment Revenue by Country (2016-2026)
7.3.2 Germany Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
7.3.3 France Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Smith-Magenis Syndrome Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Smith-Magenis Syndrome Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Smith-Magenis Syndrome Treatment Market Size by Region
8.3.1 Asia-Pacific Smith-Magenis Syndrome Treatment Revenue by Region (2016-2026)
8.3.2 China Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
8.3.5 India Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Smith-Magenis Syndrome Treatment Revenue by Type (2016-2026)
9.2 South America Smith-Magenis Syndrome Treatment Revenue by Application (2016-2026)
9.3 South America Smith-Magenis Syndrome Treatment Market Size by Country
9.3.1 South America Smith-Magenis Syndrome Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Smith-Magenis Syndrome Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Smith-Magenis Syndrome Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Smith-Magenis Syndrome Treatment Market Size by Country
10.3.1 Middle East & Africa Smith-Magenis Syndrome Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Smith-Magenis Syndrome Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Smith-Magenis Syndrome Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Smith-Magenis Syndrome Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Smith-Magenis Syndrome Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Smith-Magenis Syndrome Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Smith-Magenis Syndrome Treatment Revenue Market Share by Region (2021-2026)
Table 6. Rhythm Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Rhythm Pharmaceuticals Major Business
Table 8. Rhythm Pharmaceuticals Smith-Magenis Syndrome Treatment Product and Solutions
Table 9. Rhythm Pharmaceuticals Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Vanda Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 11. Vanda Pharmaceuticals Major Business
Table 12. Vanda Pharmaceuticals Smith-Magenis Syndrome Treatment Product and Solutions
Table 13. Vanda Pharmaceuticals Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Neurim Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 15. Neurim Pharmaceuticals Major Business
Table 16. Neurim Pharmaceuticals Smith-Magenis Syndrome Treatment Product and Solutions
Table 17. Neurim Pharmaceuticals Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Novartis Corporate Information, Head Office, and Major Competitors
Table 19. Novartis Major Business
Table 20. Novartis Smith-Magenis Syndrome Treatment Product and Solutions
Table 21. Novartis Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Takeda Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 23. Takeda Pharmaceutical Major Business
Table 24. Takeda Pharmaceutical Smith-Magenis Syndrome Treatment Product and Solutions
Table 25. Takeda Pharmaceutical Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Sanofi Corporate Information, Head Office, and Major Competitors
Table 27. Sanofi Major Business
Table 28. Sanofi Smith-Magenis Syndrome Treatment Product and Solutions
Table 29. Sanofi Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 31. Johnson & Johnson Major Business
Table 32. Johnson & Johnson Smith-Magenis Syndrome Treatment Product and Solutions
Table 33. Johnson & Johnson Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Eisai Corporate Information, Head Office, and Major Competitors
Table 35. Eisai Major Business
Table 36. Eisai Smith-Magenis Syndrome Treatment Product and Solutions
Table 37. Eisai Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 39. Teva Pharmaceutical Industries Major Business
Table 40. Teva Pharmaceutical Industries Smith-Magenis Syndrome Treatment Product and Solutions
Table 41. Teva Pharmaceutical Industries Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Boehringer Ingelheim International Corporate Information, Head Office, and Major Competitors
Table 43. Boehringer Ingelheim International Major Business
Table 44. Boehringer Ingelheim International Smith-Magenis Syndrome Treatment Product and Solutions
Table 45. Boehringer Ingelheim International Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. ALLERGAN Corporate Information, Head Office, and Major Competitors
Table 47. ALLERGAN Major Business
Table 48. ALLERGAN Smith-Magenis Syndrome Treatment Product and Solutions
Table 49. ALLERGAN Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Roche Holding Corporate Information, Head Office, and Major Competitors
Table 51. Roche Holding Major Business
Table 52. Roche Holding Smith-Magenis Syndrome Treatment Product and Solutions
Table 53. Roche Holding Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Purdue Pharma Corporate Information, Head Office, and Major Competitors
Table 55. Purdue Pharma Major Business
Table 56. Purdue Pharma Smith-Magenis Syndrome Treatment Product and Solutions
Table 57. Purdue Pharma Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. PhotoPharmics Corporate Information, Head Office, and Major Competitors
Table 59. PhotoPharmics Major Business
Table 60. PhotoPharmics Smith-Magenis Syndrome Treatment Product and Solutions
Table 61. PhotoPharmics Smith-Magenis Syndrome Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Global Smith-Magenis Syndrome Treatment Revenue (USD Million) by Players (2019-2021)
Table 63. Global Smith-Magenis Syndrome Treatment Revenue Share by Players (2019-2021)
Table 64. Breakdown of Smith-Magenis Syndrome Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 65. Smith-Magenis Syndrome Treatment Players Head Office, Products and Services Provided
Table 66. Smith-Magenis Syndrome Treatment Mergers & Acquisitions in the Past Five Years
Table 67. Smith-Magenis Syndrome Treatment New Entrants and Expansion Plans
Table 68. Global Smith-Magenis Syndrome Treatment Revenue (USD Million) by Type (2016-2021)
Table 69. Global Smith-Magenis Syndrome Treatment Revenue Share by Type (2016-2021)
Table 70. Global Smith-Magenis Syndrome Treatment Revenue Forecast by Type (2021-2026)
Table 71. Global Smith-Magenis Syndrome Treatment Revenue by Application (2016-2021)
Table 72. Global Smith-Magenis Syndrome Treatment Revenue Forecast by Application (2021-2026)
Table 73. North America Smith-Magenis Syndrome Treatment Revenue by Type (2016-2021) & (USD Million)
Table 74. North America Smith-Magenis Syndrome Treatment Revenue by Type (2021-2026) & (USD Million)
Table 75. North America Smith-Magenis Syndrome Treatment Revenue by Application (2016-2021) & (USD Million)
Table 76. North America Smith-Magenis Syndrome Treatment Revenue by Application (2021-2026) & (USD Million)
Table 77. North America Smith-Magenis Syndrome Treatment Revenue by Country (2016-2021) & (USD Million)
Table 78. North America Smith-Magenis Syndrome Treatment Revenue by Country (2021-2026) & (USD Million)
Table 79. Europe Smith-Magenis Syndrome Treatment Revenue by Type (2016-2021) & (USD Million)
Table 80. Europe Smith-Magenis Syndrome Treatment Revenue by Type (2021-2026) & (USD Million)
Table 81. Europe Smith-Magenis Syndrome Treatment Revenue by Application (2016-2021) & (USD Million)
Table 82. Europe Smith-Magenis Syndrome Treatment Revenue by Application (2021-2026) & (USD Million)
Table 83. Europe Smith-Magenis Syndrome Treatment Revenue by Country (2016-2021) & (USD Million)
Table 84. Europe Smith-Magenis Syndrome Treatment Revenue by Country (2021-2026) & (USD Million)
Table 85. Asia-Pacific Smith-Magenis Syndrome Treatment Revenue by Type (2016-2021) & (USD Million)
Table 86. Asia-Pacific Smith-Magenis Syndrome Treatment Revenue by Type (2021-2026) & (USD Million)
Table 87. Asia-Pacific Smith-Magenis Syndrome Treatment Revenue by Application (2016-2021) & (USD Million)
Table 88. Asia-Pacific Smith-Magenis Syndrome Treatment Revenue by Application (2021-2026) & (USD Million)
Table 89. Asia-Pacific Smith-Magenis Syndrome Treatment Revenue by Region (2016-2021) & (USD Million)
Table 90. Asia-Pacific Smith-Magenis Syndrome Treatment Revenue by Region (2021-2026) & (USD Million)
Table 91. South America Smith-Magenis Syndrome Treatment Revenue by Type (2016-2021) & (USD Million)
Table 92. South America Smith-Magenis Syndrome Treatment Revenue by Type (2021-2026) & (USD Million)
Table 93. South America Smith-Magenis Syndrome Treatment Revenue by Application (2016-2021) & (USD Million)
Table 94. South America Smith-Magenis Syndrome Treatment Revenue by Application (2021-2026) & (USD Million)
Table 95. South America Smith-Magenis Syndrome Treatment Revenue by Country (2016-2021) & (USD Million)
Table 96. South America Smith-Magenis Syndrome Treatment Revenue by Country (2021-2026) & (USD Million)
Table 97. Middle East & Africa Smith-Magenis Syndrome Treatment Revenue by Type (2016-2021) & (USD Million)
Table 98. Middle East & Africa Smith-Magenis Syndrome Treatment Revenue by Type (2021-2026) & (USD Million)
Table 99. Middle East & Africa Smith-Magenis Syndrome Treatment Revenue by Application (2016-2021) & (USD Million)
Table 100. Middle East & Africa Smith-Magenis Syndrome Treatment Revenue by Application (2021-2026) & (USD Million)
Table 101. Middle East & Africa Smith-Magenis Syndrome Treatment Revenue by Country (2016-2021) & (USD Million)
Table 102. Middle East & Africa Smith-Magenis Syndrome Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Smith-Magenis Syndrome Treatment Picture
Figure 2. Global Smith-Magenis Syndrome Treatment Revenue Market Share by Type in 2020
Figure 3. Medicine
Figure 4. Surgery
Figure 5. Other
Figure 6. Smith-Magenis Syndrome Treatment Revenue Market Share by Application in 2020
Figure 7. Hospital Picture
Figure 8. Specialty Clinic Picture
Figure 9. Homecare Picture
Figure 10. Other Picture
Figure 11. Global Smith-Magenis Syndrome Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Smith-Magenis Syndrome Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Smith-Magenis Syndrome Treatment Revenue Market Share by Region (2016-2026)
Figure 14. Global Smith-Magenis Syndrome Treatment Revenue Market Share by Region in 2020
Figure 15. North America Smith-Magenis Syndrome Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Smith-Magenis Syndrome Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Smith-Magenis Syndrome Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Smith-Magenis Syndrome Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Smith-Magenis Syndrome Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Smith-Magenis Syndrome Treatment Market Drivers
Figure 21. Smith-Magenis Syndrome Treatment Market Restraints
Figure 22. Smith-Magenis Syndrome Treatment Market Trends
Figure 23. Rhythm Pharmaceuticals Recent Developments and Future Plans
Figure 24. Vanda Pharmaceuticals Recent Developments and Future Plans
Figure 25. Neurim Pharmaceuticals Recent Developments and Future Plans
Figure 26. Novartis Recent Developments and Future Plans
Figure 27. Takeda Pharmaceutical Recent Developments and Future Plans
Figure 28. Sanofi Recent Developments and Future Plans
Figure 29. Johnson & Johnson Recent Developments and Future Plans
Figure 30. Eisai Recent Developments and Future Plans
Figure 31. Teva Pharmaceutical Industries Recent Developments and Future Plans
Figure 32. Boehringer Ingelheim International Recent Developments and Future Plans
Figure 33. ALLERGAN Recent Developments and Future Plans
Figure 34. Roche Holding Recent Developments and Future Plans
Figure 35. Purdue Pharma Recent Developments and Future Plans
Figure 36. PhotoPharmics Recent Developments and Future Plans
Figure 37. Global Smith-Magenis Syndrome Treatment Revenue Share by Players in 2020
Figure 38. Smith-Magenis Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 39. Global Top 3 Players Smith-Magenis Syndrome Treatment Revenue Market Share in 2020
Figure 40. Global Top 10 Players Smith-Magenis Syndrome Treatment Revenue Market Share in 2020
Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 42. Global Smith-Magenis Syndrome Treatment Revenue Share by Type in 2020
Figure 43. Global Smith-Magenis Syndrome Treatment Market Share Forecast by Type (2021-2026)
Figure 44. Global Smith-Magenis Syndrome Treatment Revenue Share by Application in 2020
Figure 45. Global Smith-Magenis Syndrome Treatment Market Share Forecast by Application (2021-2026)
Figure 46. North America Smith-Magenis Syndrome Treatment Sales Market Share by Type (2016-2026)
Figure 47. North America Smith-Magenis Syndrome Treatment Sales Market Share by Application (2016-2026)
Figure 48. North America Smith-Magenis Syndrome Treatment Revenue Market Share by Country (2016-2026)
Figure 49. United States Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Canada Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Mexico Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Europe Smith-Magenis Syndrome Treatment Sales Market Share by Type (2016-2026)
Figure 53. Europe Smith-Magenis Syndrome Treatment Sales Market Share by Application (2016-2026)
Figure 54. Europe Smith-Magenis Syndrome Treatment Revenue Market Share by Country (2016-2026)
Figure 55. Germany Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. France Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. United Kingdom Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Russia Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Italy Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Asia-Pacific Smith-Magenis Syndrome Treatment Sales Market Share by Type (2016-2026)
Figure 61. Asia-Pacific Smith-Magenis Syndrome Treatment Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific Smith-Magenis Syndrome Treatment Revenue Market Share by Region (2016-2026)
Figure 63. China Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Japan Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South Korea Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. India Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Southeast Asia Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Australia Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. South America Smith-Magenis Syndrome Treatment Sales Market Share by Type (2016-2026)
Figure 70. South America Smith-Magenis Syndrome Treatment Sales Market Share by Application (2016-2026)
Figure 71. South America Smith-Magenis Syndrome Treatment Revenue Market Share by Country (2016-2026)
Figure 72. Brazil Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Argentina Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Middle East and Africa Smith-Magenis Syndrome Treatment Sales Market Share by Type (2016-2026)
Figure 75. Middle East and Africa Smith-Magenis Syndrome Treatment Sales Market Share by Application (2016-2026)
Figure 76. Middle East and Africa Smith-Magenis Syndrome Treatment Revenue Market Share by Country (2016-2026)
Figure 77. Turkey Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. UAE Smith-Magenis Syndrome Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Methodology
Figure 81. Research Process and Data Source

以下、関連資料のご紹介

世界のQT延長症候群治療市場 2021：企業別、地域別、種類・用途別

Global Long QT Syndrome Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12434 2021年7月 101Pages
当調査資料では、QT延長症候群治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。QT延長症候群治療の種類別市場規模（医療、外科療法）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジ...

世界のクリッペル・トレノネー症候群治療市場 2021：企業別、地域別、種類・用途別

Global Klippel Trenaunay Syndrome Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12418 2021年7月 102Pages
当調査資料では、クリッペル・トレノネー症候群治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。クリッペル・トレノネー症候群治療の種類別市場規模（薬物療法、レーザー治療、硬化療法、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北...

世界の全身性炎症反応症候群治療市場 2021：企業別、地域別、種類・用途別

Global Systemic Inflammatory Response Syndrome Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A11927 2021年7月 107Pages
当調査資料では、全身性炎症反応症候群治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。全身性炎症反応症候群治療の種類別市場規模（髄膜炎、尿路感染症（UTI）、肺炎、自己免疫疾患、その他）、用途別市場規模（病院・外来手術センター、専門クリニック、その他...

世界の咳過敏症症候群治療市場 2021：企業別、地域別、種類・用途別

Global Cough Hypersensitivity Syndrome Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12189 2021年7月 108Pages
当調査資料では、咳過敏症症候群治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。咳過敏症症候群治療の種類別市場規模（鎮咳薬、吸入コルチコステロイド、抗コリン作用薬、その他）、用途別市場規模（病院、小売薬局、オンライン薬局、その他）、地域別市場規模（北...

世界のダンピング症候群治療市場 2021：企業別、地域別、種類・用途別

Global Dumping Syndrome Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12238 2021年7月 103Pages
当調査資料では、ダンピング症候群治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ダンピング症候群治療の種類別市場規模（医療、外科療法）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南...

Global HIV Associated Lipodystrophy Syndrome Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12340 2021年7月 107Pages
当調査資料では、HIV関連リポジストロフィー症候群治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。HIV関連リポジストロフィー症候群治療の種類別市場規模（特定薬物治療、美容矯正治療）、用途別市場規模（病院、専門クリニック、その他）、地域別市場規模（...

世界のレット症候群治療市場 2021：企業別、地域別、種類・用途別

Global Rett Syndrome Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12670 2021年7月 95Pages
当調査資料では、レット症候群治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。レット症候群治療の種類別市場規模（BHV-5000、ブリオスタチン-1、CPT-157633、ELX-02、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場...

世界の急性呼吸窮迫症候群治療薬市場 2021：企業別、地域別、種類・用途別

Global Acute Respiratory Distress Syndrome Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12023 2021年7月 90Pages
当調査資料では、急性呼吸窮迫症候群治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。急性呼吸窮迫症候群治療薬の種類別市場規模（メチルプレドニゾロン、ヒドロコルチゾン、注射用子牛肺サーファクタント、その他）、用途別市場規模（入院患者、外来患者）、地域...

世界のレノックス・ガストー症候群治療薬市場 2021：企業別、地域別、種類・用途別

Global Lennox-Gastaut Syndrome Drug Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-107A14323 2021年7月 77Pages
当調査資料では、レノックス・ガストー症候群治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。レノックス・ガストー症候群治療薬の種類別市場規模（ペランパネル、カンナビジオール、NRP-2945、塩酸フェンフルラミン、その他）、用途別市場規模（病院、ク...

世界のQT延長症候群治療市場予測（～2024年）

Global Long QT Syndrome Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR09D4092 2019年9月18日 124Pages
本調査レポートは、QT延長症候群治療の世界市場について調べ、まとめました。種類別セグメントは、薬物療法、外科療法等、用途別セグメントは、病院、診療所、その他等に区分しました。QT延長症候群治療の世界市場概観、企業動向、企業別QT延長症候群治療シェア、市場規模推移、市場規模予測（2019年-2024年...

世界のクリッペル・トレノネー症候群治療市場 2021：企業別、地域別、種類・用途別 The Klippel Trenaunay Syndrome Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
世界の全身性炎症反応症候群治療市場 2021：企業別、地域別、種類・用途別 The Systemic Inflammatory Response Syndrome Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain o…
世界のダンピング症候群治療市場 2021：企業別、地域別、種類・用途別 The Dumping Syndrome Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…
世界のクリッペルトレノー症候群治療市場予測（～2024年） Klippel–Trenaunay Syndrome (KTS or KT) is a rare congenital medical condition in which blood vessels and/or lymph vessels fail to form properly. The three main features are nevus flammeus (port-wine stain), venous and lymphatic malformations, and soft-tissue hypertrophy of the affected limb. It is s…
世界のQT延長症候群治療市場 2021：企業別、地域別、種類・用途別 The Long QT Syndrome Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…